

Edgar Filing: NOVO NORDISK A S - Form 6-K

NOVO NORDISK A S
Form 6-K
September 15, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

September 15, 2009

NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)

NOVO ALLE
DK-2880, BAGSVAERD
DENMARK
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g-32(b):82-_____

TRANSACTION IN OWN SHARES

NOVO NORDISK A/S - SHARE REPURCHASE PROGRAMME

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in
accordance with the provisions of the European Commission's regulation no
2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Edgar Filing: NOVO NORDISK A S - Form 6-K

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.4 billion in the period from 10 August 2009 to 18 December 2009.

Since the announcement as of 7 September 2009, the following transactions have been made under the programme:

	NUMBER OF SHARES	AVERAGE PURCHASE PRICE	TRANSACTION VALUE, DKK
ACCUMULATED, LAST ANNOUNCEMENT	1,521,000		479,133,986
7 September 2009	55,000	316.5500	17,410,250
8 September 2009	66,000	319.0900	21,059,940
9 September 2009	75,000	318.5030	23,887,725
10 September 2009	75,000	322.2300	24,167,250
11 September 2009	75,000	326.5450	24,490,875
ACCUMULATED UNDER THE PROGRAMME	1,867,000		590,150,026

With the transactions stated above, Novo Nordisk owns a total of 26,703,808 treasury shares, corresponding to 4.3% of the share capital. The total amount of shares in the company is 620,000,000 including treasury shares.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Media:

Outside North America:

Mette Kruse Danielsen

Tel: (+45) 4442 3883

mkd@novonordisk.com

In North America:

Sean Clements

Tel: (+1) 609 514 8316

secl@novonordisk.com

Investors:

Outside North America:

Mads Veggerby Lausten

Tel: (+45) 4443 7919

mlau@novonordisk.com

Kasper Roseeuw Poulsen

Tel: 4442 4471

krop@novonordisk.com

In North America:

Hans Rommer

Tel: (+1) 609 919 7937

hrmm@novonordisk.com

Company Announcement No 54 / 2009

Edgar Filing: NOVO NORDISK A S - Form 6-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: September 15, 2009

NOVO NORDISK A/S

Lars Rebien Sorensen,
President and Chief Executive Officer